AYTU BIOPHARMA, INC short interest in 2023
In 2023, AYTU BIOPHARMA, INC's disclosed short interest ran from 12.31% of shares outstanding on 15 Feb 2023 to 6.76% on 29 Dec 2023, a change of -5.55 percentage points. The year's high was 16.31% on 15 Jun 2023 and its low 6.32% on 29 Sep 2023, averaging 11.32% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.36 days on 15 Sep 2023. Full history: AYTU BIOPHARMA, INC.
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 12.31% (15 Feb 2023)
- End of year
- 6.76% (29 Dec 2023)
- Change
- -5.55 pp
- High
- 16.31% (15 Jun 2023)
- Low
- 6.32% (29 Sep 2023)
- Average
- 11.32%
- Highest days to cover
- 18.36 (15 Sep 2023)
- SEC filings marked
- 9
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Feb 2023 | 12.31% | 9.50 | |
| 28 Feb 2023 | 13.82% | 6.81 | 10-Q filed, results (8-K) |
| 15 Mar 2023 | 13.93% | 8.39 | |
| 31 Mar 2023 | 14.36% | 10.22 | |
| 14 Apr 2023 | 14.95% | 14.61 | |
| 28 Apr 2023 | 13.52% | 3.15 | |
| 15 May 2023 | 15.80% | 4.56 | 10-Q filed, results (8-K) |
| 31 May 2023 | 15.79% | 10.94 | |
| 15 Jun 2023 | 16.31% | 8.78 | |
| 30 Jun 2023 | 9.91% | 4.60 | |
| 14 Jul 2023 | 9.03% | 14.12 | |
| 31 Jul 2023 | 8.47% | 11.24 | |
| 15 Aug 2023 | 8.33% | 10.39 | |
| 31 Aug 2023 | 9.33% | 13.21 | |
| 15 Sep 2023 | 8.74% | 18.36 | |
| 29 Sep 2023 | 6.32% | 1.00 | results (8-K) |
| 13 Oct 2023 | 13.44% | 6.63 | 10-K filed |
| 31 Oct 2023 | 11.44% | 8.34 | results (8-K) |
| 15 Nov 2023 | 10.83% | 8.48 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 8.33% | 16.43 | |
| 15 Dec 2023 | 7.36% | 14.25 | |
| 29 Dec 2023 | 6.76% | 11.24 |
See also: AYTU BIOPHARMA, INC's full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.